During the past decade, ASL Viterbo - Ospedale Belcolle conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 3 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ASL Viterbo - Ospedale Belcolle" #1 sponsor was "National Cancer Institute, Naples" with 4 trials, followed by "Abbott Medical Devices" with 1 trials sponsored, "Ascelia Pharma AB" with 1 trials sponsored, "Calliditas Therapeutics AB" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ASL Viterbo - Ospedale Belcolle" #1 collaborator was "Mario Negri Institute for Pharmacological Research" with 1 trials as a collaborator, "Niguarda Hospital" with 1 trials as a collaborator, "Società Italiana di Nefrologia" with 1 trials as a collaborator and "University of Campania "Luigi Vanvitelli"" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "ASL Viterbo - Ospedale Belcolle" are "Breast Cancer" (2 trials), "Non-small Cell Lung Cancer Metastatic" (2 trials), "Non-small Cell Lung Cancer Stage IIIB" (2 trials), "Breast Neoplasm" (1 trials) and "Chronic Renal Failure" (1 trials). Many other conditions were trialed in "ASL Viterbo - Ospedale Belcolle" in a lesser frequency.

Most popular intervention types in "ASL Viterbo - Ospedale Belcolle" are "Drug" (13 trials), "Other" (2 trials), "Biological" (1 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cisplatin" (2 trials), "Erlotinib" (2 trials), "Gemcitabine" (2 trials), "Placebo" (2 trials) and "25-OH-D vitamin" (1 trials). Other intervention names were less common.

The vast majority of trials in "ASL Viterbo - Ospedale Belcolle" are 14 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "ASL Viterbo - Ospedale Belcolle". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in ASL Viterbo - Ospedale Belcolle, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in ASL Viterbo - Ospedale Belcolle, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".